var data={"title":"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/contributors\" class=\"contributor contributor_credentials\">Christine Johnston, MD, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/contributors\" class=\"contributor contributor_credentials\">Anna Wald, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 16, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H6231103\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Herpes simplex virus type 2 (HSV-2) is the leading cause of genital ulcer disease (GUD) worldwide [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/1-5\" class=\"abstract_t\">1-5</a>]. HIV-infected persons have a higher prevalence of HSV-2 infection, an increased risk of asymptomatic HSV genital shedding, and may have unusual clinical manifestations of HSV-2-related disease compared with HSV-2-seropositive patients who are HIV-uninfected. </p><p>This topic will review the epidemiology, clinical manifestations and diagnosis of HSV-2 infection in the HIV-infected host. The treatment of genital HSV in the HIV-infected host and the viral interactions between HIV and HSV-2 are discussed elsewhere. (See <a href=\"topic.htm?path=effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention\" class=\"medical medical_review\">&quot;Effect of herpes simplex virus on HIV infection: Implications for HIV prevention&quot;</a> and <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-type-2-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus type 2 in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=treatment-of-drug-resistant-genital-herpes-simplex-virus-infection-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H970262\"><span class=\"h1\">DEFINITIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical designations of genital HSV infection are: primary, nonprimary first episode, and recurrent or reactivation disease (<a href=\"image.htm?imageKey=ID%2F80693\" class=\"graphic graphic_table graphicRef80693 \">table 1</a>). Among patients presenting with first episode of genital herpes, both virologic and serologic information is needed to accurately define the category of infection. </p><p class=\"headingAnchor\" id=\"H970224\"><span class=\"h2\">Primary</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary infection refers to HSV infection in a patient without pre-existing antibodies to either HSV-1 or HSV-2. </p><p class=\"headingAnchor\" id=\"H970231\"><span class=\"h2\">Nonprimary</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nonprimary first episode infection refers to the acquisition of genital HSV-1 in a patient with preexisting antibodies to HSV-2 or the acquisition of genital HSV-2 in a patient with preexisting antibodies to HSV-1. Most HIV-infected adults with a first episode HSV infection have nonprimary infection because of prior exposure to HSV-1 [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/6,7\" class=\"abstract_t\">6,7</a>]. </p><p class=\"headingAnchor\" id=\"H970361\"><span class=\"h2\">Reactivation disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antiviral treatment during newly acquired infection lessens morbidity, but does not eradicate latent virus, which can subsequently reactivate in immunocompetent or immunocompromised hosts. Patients with a new diagnosis of HSV-2 infection should be counseled to expect recurrence of genital ulcers. In addition, a substantial proportion of patients seen with their first clinical episode of genital herpes actually have recurrent disease. </p><p class=\"headingAnchor\" id=\"H2392163\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Epidemiologic studies demonstrate that HSV-2 seroprevalence is disproportionately higher among HIV-infected persons compared with HIV-seronegative persons with comparable demographic and behavioral risk factors for HSV-2 acquisition [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/8-12\" class=\"abstract_t\">8-12</a>]. Additional studies conducted around the world show increased HSV-2 seroprevalence in HIV-infected persons:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a surveillance study of 3280 Peruvian men who have sex with men (MSM), a significantly greater proportion of HIV-seropositive men were coinfected with HSV-2 compared with HIV-seronegative men (81 versus 41 percent) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/13\" class=\"abstract_t\">13</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Similarly, in a cohort of 300 women in the Central African Republic, a significantly greater proportion of HIV-infected women were HSV-2-seropositive compared with HIV-seronegative women (91 versus 78 percent) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/14\" class=\"abstract_t\">14</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a prospective cohort of 700 HIV-infected persons in the United States, 60 percent of HIV-infected persons were HSV-2-seropositive, which is threefold higher than among the general US population [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"headingAnchor\" id=\"H2392466\"><span class=\"h1\">NATURAL HISTORY</span></p><p class=\"headingAnchor\" id=\"H744885\"><span class=\"h2\">Clinical disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The natural history of HSV-2 infection is altered among patients with HIV infection [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/16\" class=\"abstract_t\">16</a>]. Among HSV-2 seropositive patients, concomitant HIV infection is associated with [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/17-21\" class=\"abstract_t\">17-21</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased frequency and severity of HSV-2 reactivation disease </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atypical clinical manifestations of HSV-2 reactivation episodes </p><p/><p>Among immunocompetent hosts, an average of four recurrences will occur during the first year after acquisition; recurrent genital lesions generally resolve within a median of four days with antiviral therapy [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/22\" class=\"abstract_t\">22</a>]. In comparison with HIV-seronegative persons, genital HSV-2 recurrences in HIV-infected patients are more frequent and the episodes are of longer duration [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/23-26\" class=\"abstract_t\">23-26</a>].</p><p>Persistent, non-healing lesions caused by HSV-2 are more common in patients with advanced immunosuppression (eg, CD4 cell counts less than 100 <span class=\"nowrap\">cells/mm<sup>3</sup>)</span> [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/17,24\" class=\"abstract_t\">17,24</a>], supporting the importance of cell-mediated immunity in controlling genital herpes. In addition, severe genital ulcers are associated with impaired HSV-specific CD8+ cytotoxic T-cell responses in HIV-infected persons [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/27\" class=\"abstract_t\">27</a>]. (See <a href=\"#H6231117\" class=\"local\">'Ulcerative disease'</a> below.)</p><p class=\"headingAnchor\" id=\"H744892\"><span class=\"h2\">Viral shedding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HSV-2 is detected frequently from mucosal genital surfaces in the absence of genital ulcerative disease, referred to as &ldquo;subclinical shedding&rdquo; [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/28,29\" class=\"abstract_t\">28,29</a>]. HSV-2 shedding is more frequent among HIV-infected men [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/25\" class=\"abstract_t\">25</a>] and women [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/19,30\" class=\"abstract_t\">19,30</a>] compared with HIV-seronegative persons. Among HIV-infected patients, the risk of HSV-2 shedding, as measured by polymerase chain reaction (PCR), is approximately six-fold greater among those patients with CD4 cell counts &lt;200 <span class=\"nowrap\">cells/mm<sup>3</sup></span> [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/31\" class=\"abstract_t\">31</a>]. Increased rates of HSV-2 detection in the genital tract, using culture-based methods, are associated with higher plasma HIV-1 RNA levels [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/32\" class=\"abstract_t\">32</a>]. (See <a href=\"topic.htm?path=effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention\" class=\"medical medical_review\">&quot;Effect of herpes simplex virus on HIV infection: Implications for HIV prevention&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13152652\"><span class=\"h2\">Effect of antiretroviral therapy on HSV-2-related disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Small observational studies report conflicting results as to whether antiretroviral therapy (ART) ameliorates HSV-related ulcers and viral shedding among HIV-infected patients with immunosuppression [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/8,33,34\" class=\"abstract_t\">8,33,34</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an observational study of 77 HIV-infected persons with recurrent disease, ART was associated with fewer days with genital ulceration (3 percent versus 11 percent of days); however, no significant change in the frequency or quantity of HSV-2 shedding was seen [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/33\" class=\"abstract_t\">33</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the Women&rsquo;s Interagency HIV Study (WIHS), the frequency of genital ulcers did not change with the initiation of ART; genital HSV-2 shedding was not measured [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"headingAnchor\" id=\"H11525287\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, the HIV-infected patient usually presents with HSV-related reactivation disease; the clinical manifestations are influenced by the patient&rsquo;s current and prior immunologic status, as evidenced by CD4 cell counts [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/18,21\" class=\"abstract_t\">18,21</a>]. (See <a href=\"#H970262\" class=\"local\">'Definitions'</a> above.)</p><p class=\"headingAnchor\" id=\"H6231117\"><span class=\"h2\">Ulcerative disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with well-controlled HIV disease, HSV-2-related genital ulcerations may range from painless ulcers [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/25,29,35\" class=\"abstract_t\">25,29,35</a>] to typical shallow, erosive genital lesions approximately 2 to 7 millimeters in size. Symptoms of genital ulcers can include pain, tingling, and pruritis. Patients with ulcers near the urethra may complain of external dysuria. Others may have only subclinical shedding of virus without any mucocutaneous lesions, even during a careful examination [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/23\" class=\"abstract_t\">23</a>].</p><p>However, in the patient with AIDS, deep genital or perianal ulcerations or fissures have been described, which can be quite painful [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/25,26,36\" class=\"abstract_t\">25,26,36</a>]. In the era prior to ART, chronic expanding ulcerative perianal lesions associated with HSV-2 infection were commonly observed among patients with severe immunosuppression (eg, CD4 counts &lt;50 <span class=\"nowrap\">cells/mm<sup>3</sup>)</span> [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/17,37\" class=\"abstract_t\">17,37</a>]. Of note, persistent mucocutaneous HSV-2-related ulcers lasting greater than one month were among the first opportunistic infections to be classified as an AIDS-defining event (<a href=\"image.htm?imageKey=ID%2F81569\" class=\"graphic graphic_picture graphicRef81569 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/26,36,38\" class=\"abstract_t\">26,36,38</a>]. These patients often had fever and weight loss related to other concomitant opportunistic infections [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/36\" class=\"abstract_t\">36</a>]. </p><p class=\"headingAnchor\" id=\"H6231124\"><span class=\"h2\">Hypertrophic masses and pseudotumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atypical manifestations of HSV-2 infection described in HIV-infected patients include hypertrophic masses, pseudotumors, nodular, or plaque-like lesions, which may be mistaken for squamous cell carcinoma of the vulva, scrotum, or other malignancies (<a href=\"image.htm?imageKey=ID%2F63362\" class=\"graphic graphic_picture graphicRef63362 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/18,26,39-45\" class=\"abstract_t\">18,26,39-45</a>]. Hypertrophic lesions are often observed among patients with advanced immunodeficiency (eg, CD4 counts &lt;50 <span class=\"nowrap\">cells/mm<sup>3</sup>)</span>. This type of lesion can also be seen in a patient with a history of recurrent herpes and a low nadir CD4 cell count, despite ART-associated improvements in CD4 cell counts and HIV RNA suppression [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/18,26,45\" class=\"abstract_t\">18,26,45</a>]. </p><p>Hypertrophic lesions may also be found in ectopic locations including the orofacial area or the endobronchial tree [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/18,46,47\" class=\"abstract_t\">18,46,47</a>]. Genital HSV-2 lesions mimicking condyloma acuminata secondary to human papillomavirus infection have also been described (<a href=\"image.htm?imageKey=ID%2F75196\" class=\"graphic graphic_picture graphicRef75196 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/48\" class=\"abstract_t\">48</a>]. (See <a href=\"topic.htm?path=condylomata-acuminata-anogenital-warts-in-adults-epidemiology-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6231138\"><span class=\"h2\">Other unusual manifestations of HSV disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>More serious clinical presentations of HSV reactivation include esophagitis, tracheitis, meningoencephalitis, hepatitis, pneumonitis, retinal necrosis, and disseminated disease, which are rare among HIV-seropositive patients [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/49,50\" class=\"abstract_t\">49,50</a>]. However, herpetic lesions in atypical locations, such as the back, face or fingers (paronychia) [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/37\" class=\"abstract_t\">37</a>] do occur and thus HSV should be considered in the differential of cutaneous lesions outside of the genital area. </p><p>Severe genital ulcers may occur in patients starting on antiretroviral therapy as part of the Immune Reconstitution Inflammatory Response (IRIS). The prevalence of IRIS and its implications for treatment of HIV and HSV are discussed in detail elsewhere. (See <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-type-2-in-hiv-infected-patients#H4856507\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus type 2 in HIV-infected patients&quot;, section on 'Immune reconstitution syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H6231152\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A clinical diagnosis of genital herpes infection should be confirmed with diagnostic testing; this is particularly true in the HIV-infected individual where the clinical manifestations of disease may be altered. The diagnostic approach is similar to that in the HIV-seronegative patient [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/23\" class=\"abstract_t\">23</a>]. Techniques include viral culture, polymerase chain reaction (PCR), and type-specific serologic tests. Occasionally, a biopsy may be required, as discussed below. </p><p class=\"headingAnchor\" id=\"H11525273\"><span class=\"h2\">Ulcerative disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cell culture and PCR-based testing are commonly used for a patient presenting with active lesions. Although both culture and PCR can determine the type of genital herpes (HSV-1 or HSV-2), PCR-based testing has greater overall sensitivity than culture [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/23\" class=\"abstract_t\">23</a>]. The diagnostic yield of either test is highest when the sample is taken from the base of a ruptured vesicle; the diagnostic yield declines rapidly as the lesion heals. Serologic testing may be the preferred diagnostic test in patients with healing or small atypical lesions.</p><p>Details on the performance of these various tests are found elsewhere. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection#H24\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H11525280\"><span class=\"h2\">Hypertrophic lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A high index of suspicion for HSV-2 infection is needed in patients with pseudotumors or hypertrophic lesions, which can be mistaken for papillomatous lesions or other genital pathology. Surface samples of the lesion should be sent for PCR testing; if PCR testing is not available, a viral culture may be sent. If laboratory testing is not informative, the lesion should be biopsied for examination for viral inclusions [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/26\" class=\"abstract_t\">26</a>]. Histologically, these tumors may be characterized by pseudoepitheliomatous hyperplasia, which may be difficult to differentiate from squamous cell carcinoma [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/41,44,45\" class=\"abstract_t\">41,44,45</a>]. Dermatologic consultation is advised if the diagnosis is uncertain.</p><p class=\"headingAnchor\" id=\"H12678014\"><span class=\"h2\">Patients with a recent history of genital disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serologic testing may also be helpful in the patient with a history of recent genital ulcers who does not have any clinical findings on examination; antibodies to HSV-2 usually develop within 12 weeks after newly acquired infection [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/51\" class=\"abstract_t\">51</a>]. Serologic testing performance appears to vary by assay. Caution is suggested in interpreting low titer positive results, as false positive tests can occur in both HIV-infected and HIV-uninfected persons [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/52\" class=\"abstract_t\">52</a>].</p><p>Routine serologic screening for HSV-2 in the asymptomatic patient is discussed below. (See <a href=\"#H11524735\" class=\"local\">'Screening for HSV-2 infection'</a> below.)</p><p class=\"headingAnchor\" id=\"H11524576\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HSV-2 is the leading cause of genital ulcer disease in both HIV-infected [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/53\" class=\"abstract_t\">53</a>] and HIV-uninfected persons [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/1,54\" class=\"abstract_t\">1,54</a>]. The differential diagnosis of genital ulcerative disease, regardless of HIV status, includes other sexually transmitted diseases, such as syphilis and chancroid. </p><p>Painful ulcers tend to be more typical of HSV and chancroid, while ulcers associated with syphilis, lymphogranuloma venereum (LGV), and granuloma inguinale are usually painless. HSV-related ulcers are also usually recurrent by history. However, a clinical diagnosis made solely on these distinctions may be misleading, emphasizing the importance of laboratory testing. Noninfectious etiologies include fixed drug reactions, Beh&ccedil;et&rsquo;s syndrome, neoplasms, and trauma. (See <a href=\"topic.htm?path=approach-to-the-patient-with-genital-ulcers#H406530882\" class=\"medical medical_review\">&quot;Approach to the patient with genital ulcers&quot;, section on 'General approach'</a>.)</p><p>Routine diagnostic evaluation of a patient with genital ulcers includes HSV culture or PCR testing for HSV and a screening test for syphilis, such as a rapid plasma reagin (RPR). The decision to test for chancroid will be influenced by epidemiologic risk factors, such as travel to an endemic area. (See <a href=\"topic.htm?path=approach-to-the-patient-with-genital-ulcers#H406530882\" class=\"medical medical_review\">&quot;Approach to the patient with genital ulcers&quot;, section on 'General approach'</a>.)</p><p>In patients with atypical manifestations or hypertrophic lesions or masses, the differential diagnosis is broad and includes a variety of dermatologic disorders of the genital skin and mucosa, such as HPV infection. Malignancy must also be considered in the differential diagnosis, since cancer is an increasing cause of morbidity and mortality among HIV-infected patients in the era of potent ART [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/55\" class=\"abstract_t\">55</a>]. If treatment of documented HSV infection does not lead to resolution, drug-resistant HSV or an alternative diagnosis must be considered [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/56\" class=\"abstract_t\">56</a>]. Dermatologic consultation and a skin biopsy may be required. (See <a href=\"topic.htm?path=hiv-infection-and-malignancy-epidemiology-and-pathogenesis\" class=\"medical medical_review\">&quot;HIV infection and malignancy: Epidemiology and pathogenesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11524735\"><span class=\"h1\">SCREENING FOR HSV-2 INFECTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We screen HIV-infected individuals with a CD4 count &lt;250 <span class=\"nowrap\">cells/microL</span> for herpes simplex 2 (HSV-2) using HSV type-specific serology, even if they are asymptomatic [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/57,58\" class=\"abstract_t\">57,58</a>]. For those who have evidence of HSV-2 and are initiating antiretroviral therapy, we administer suppressive antiviral therapy for HSV-2 (ie, <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>, <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>) to reduce the risk of developing an HSV-2 related immune reconstitution inflammatory syndrome (IRIS). A more detailed discussion on HSV-2 associated IRIS is found elsewhere. (See <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-type-2-in-hiv-infected-patients#H4856507\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus type 2 in HIV-infected patients&quot;, section on 'Immune reconstitution syndrome'</a>.)</p><p>HSV-2 serologic testing may also be reasonable for patients with a CD4 count &ge;250 <span class=\"nowrap\">cells/microL</span> as a way to inform counseling on how to reduce the risk of HSV-2 acquisition and transmission. As an example, condoms can reduce the risk of HSV transmission to an HSV-uninfected partner, and may be particularly useful in preventing transmission from HSV-2-infected men to HSV-2-uninfected women [<a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/59-61\" class=\"abstract_t\">59-61</a>]. In addition, suppressive antiviral therapy may reduce the risk of HSV transmission in certain scenarios. The use of suppressive therapy to prevent HSV transmission is reviewed separately. (See <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-type-2-in-hiv-infected-patients#H6008946\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus type 2 in HIV-infected patients&quot;, section on 'Suppressive therapy'</a> and <a href=\"topic.htm?path=prevention-of-genital-herpes-virus-infections#H10\" class=\"medical medical_review\">&quot;Prevention of genital herpes virus infections&quot;, section on 'Chronic suppressive therapy in discordant couples'</a>.)</p><p class=\"headingAnchor\" id=\"H2974930377\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-sexually-transmitted-infections\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Sexually transmitted infections&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Opportunistic infections in HIV-infected adults and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6231095\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Herpes simplex virus type 2 (HSV-2) is the leading cause of genital ulcer disease (GUD) worldwide. (See <a href=\"#H6231103\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical designations of genital HSV infection are: primary, nonprimary first episode, and recurrent or reactivation disease. Nonprimary first episode infection refers to the acquisition of genital HSV-1 in a patient with preexisting antibodies to HSV-2 or the acquisition of genital HSV-2 in a patient with preexisting antibodies to HSV-1 (eg, an individual with prior orolabial herpes and an HSV-1 antibody response develops genital herpes due to acquisition of HSV-2 infection). Most HIV-infected adults with a first episode HSV infection have nonprimary infection because of prior exposure to HSV-1. (See <a href=\"#H970262\" class=\"local\">'Definitions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiviral treatment during newly acquired infection lessens morbidity, but does not eradicate latent virus, which can subsequently reactivate in immunocompetent or immunocompromised hosts. (See <a href=\"#H970361\" class=\"local\">'Reactivation disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epidemiologic studies demonstrate that HSV-2 seroprevalence is disproportionately higher among HIV-infected persons compared with HIV-seronegative persons. (See <a href=\"#H2392163\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The natural history of HSV-2 infection is altered among patients with HIV infection. Among HSV-seropositive patients, concomitant HIV infection is associated with increased frequency and severity of genital ulcers. Advanced immunosuppression is associated with an increased risk of persistent non-healing ulcers and higher rates of subclinical viral shedding, which increases the risk of HSV-2 transmission. (See <a href=\"#H2392466\" class=\"local\">'Natural history'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical manifestations of HSV-2 infection vary according to the patient&rsquo;s immunologic status. Genital ulcerations may range from unnoticed ulcers to typical herpetic lesions in the patient with well-controlled HIV infection to large, deep genital or perianal ulcerations in persons with advanced AIDS. Atypical presentations include pseudotumors or hypertrophic masses. (See <a href=\"#H11525287\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A clinical diagnosis of genital herpes infection should be confirmed with diagnostic laboratory testing; this is particularly true in the HIV-infected individual where the clinical manifestations of disease may be altered. The diagnostic approach is similar to that in the HIV-seronegative patient. Techniques include: polymerase chain reaction (PCR), viral culture, and type-specific serologic tests. The choice of test will vary depending on the clinical presentation. (See <a href=\"#H6231152\" class=\"local\">'Diagnosis'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For HIV-infected individuals with a CD4 count &lt;250 <span class=\"nowrap\">cells/microL,</span> we perform serologic screening for HSV-2, even if they are asymptomatic. For those who are HSV-2 seropositive and are initiating antiretroviral therapy, we administer suppressive antiviral therapy (ie, <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>, <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>) to reduce the risk of developing an HSV-associated immune reconstitution inflammatory syndrome. HSV-2 serologic testing is also reasonable for patients with a CD4 count &ge;250 <span class=\"nowrap\">cells/microL</span> as a way to inform counseling on how to reduce the risk of HSV-2 acquisition and transmission. (See <a href=\"#H11524735\" class=\"local\">'Screening for HSV-2 infection'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/1\" class=\"nounderline abstract_t\">Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998; 178:1795.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/2\" class=\"nounderline abstract_t\">Nilsen A, Kasubi MJ, Mohn SC, et al. Herpes simplex virus infection and genital ulcer disease among patients with sexually transmitted infections in Dar es Salaam, Tanzania. Acta Derm Venereol 2007; 87:355.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/3\" class=\"nounderline abstract_t\">Brankin AE, Tobian AA, Laeyendecker O, et al. Aetiology of genital ulcer disease in female partners of male participants in a circumcision trial in Uganda. Int J STD AIDS 2009; 20:650.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/4\" class=\"nounderline abstract_t\">Beyrer C, Jitwatcharanan K, Natpratan C, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998; 178:243.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/5\" class=\"nounderline abstract_t\">Sanchez J, Volquez C, Totten PA, et al. The etiology and management of genital ulcers in the Dominican Republic and Peru. Sex Transm Dis 2002; 29:559.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/6\" class=\"nounderline abstract_t\">Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964.</a></li><li class=\"breakAll\">http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/ (Accessed on January 06, 2012).</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/8\" class=\"nounderline abstract_t\">Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006; 20:1051.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/9\" class=\"nounderline abstract_t\">Rabenau HF, Lennemann T, Kircher C, et al. Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho. Sex Transm Dis 2010; 37:454.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/10\" class=\"nounderline abstract_t\">Boulos R, Ruff AJ, Nahmias A, et al. Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type I infections. The Johns Hopkins University (JHU)/Centre pour le Developpement et la Sant&eacute; (CDS) HIV Study Group. J Infect Dis 1992; 166:418.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/11\" class=\"nounderline abstract_t\">Romanowski B, Myziuk LN, Walmsley SL, et al. Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada. Sex Transm Dis 2009; 36:165.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/12\" class=\"nounderline abstract_t\">Gwanzura L, McFarland W, Alexander D, et al. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J Infect Dis 1998; 177:481.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/13\" class=\"nounderline abstract_t\">Lama JR, Lucchetti A, Suarez L, et al. Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru. J Infect Dis 2006; 194:1459.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/14\" class=\"nounderline abstract_t\">Mbopi-K&eacute;ou FX, Gr&eacute;senguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/15\" class=\"nounderline abstract_t\">Patel P, Bush T, Mayer KH, et al. Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States. Sex Transm Dis 2012; 39:154.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/16\" class=\"nounderline abstract_t\">Schacker T. The role of HSV in the transmission and progression of HIV. Herpes 2001; 8:46.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/17\" class=\"nounderline abstract_t\">Bagdades EK, Pillay D, Squire SB, et al. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS 1992; 6:1317.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/18\" class=\"nounderline abstract_t\">Cury K, Valin N, Gozlan J, et al. Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient. Sex Transm Dis 2010; 37:126.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/19\" class=\"nounderline abstract_t\">Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995; 123:845.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/20\" class=\"nounderline abstract_t\">DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/21\" class=\"nounderline abstract_t\">Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/22\" class=\"nounderline abstract_t\">Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996; 156:1729.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/23\" class=\"nounderline abstract_t\">Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370:2127.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/24\" class=\"nounderline abstract_t\">Aumakhan B, Gaydos CA, Quinn TC, et al. Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010; 5:e9973.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/25\" class=\"nounderline abstract_t\">Schacker T, Zeh J, Hu HL, et al. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/26\" class=\"nounderline abstract_t\">Mosunjac M, Park J, Wang W, et al. Genital and perianal herpes simplex simulating neoplasia in patients with AIDS. AIDS Patient Care STDS 2009; 23:153.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/27\" class=\"nounderline abstract_t\">Posavad CM, Koelle DM, Shaughnessy MF, Corey L. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 1997; 94:10289.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/28\" class=\"nounderline abstract_t\">Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/29\" class=\"nounderline abstract_t\">Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/30\" class=\"nounderline abstract_t\">Mbopi Keou FX, Gr&eacute;senguet G, Mayaud P, et al. Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS 1999; 13:536.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/31\" class=\"nounderline abstract_t\">Mostad SB, Kreiss JK, Ryncarz A, et al. Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1. Am J Obstet Gynecol 2000; 183:948.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/32\" class=\"nounderline abstract_t\">Wright PW, Hoesley CJ, Squires KE, et al. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis 2003; 36:207.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/33\" class=\"nounderline abstract_t\">Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004; 190:693.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/34\" class=\"nounderline abstract_t\">Mayaud P, Nagot N, Konat&eacute; I, et al. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex Transm Infect 2008; 84:332.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/35\" class=\"nounderline abstract_t\">Sandlin MI, Johnston C, Bowe D, et al. Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men. Sex Transm Dis 2011; 38:833.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/36\" class=\"nounderline abstract_t\">Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981; 305:1439.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/37\" class=\"nounderline abstract_t\">Mindel A, Carney O, Williams P. Cutaneous herpes simplex infections. Genitourin Med 1990; 66:14.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/38\" class=\"nounderline abstract_t\">1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/39\" class=\"nounderline abstract_t\">Yudin MH, Kaul R. Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy. Infect Dis Obstet Gynecol 2008; 2008:592532.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/40\" class=\"nounderline abstract_t\">Maharaj R, Parboosing R, Moodley M, et al. An unusual hypertrophic genital mass lesion--a diagnostic and treatment dilemma. J Clin Virol 2009; 46:303.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/41\" class=\"nounderline abstract_t\">Frimer M, Chudnoff S, Hebert T, Shahabi S. Pseudoepitheliomatous hyperplasia mimicking vulvar cancer in a patient with AIDS. J Low Genit Tract Dis 2011; 15:66.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/42\" class=\"nounderline abstract_t\">Boothby M, Radcliffe K. An unusual vulval lesion in an HIV-infected woman. Int J STD AIDS 2007; 18:218.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/43\" class=\"nounderline abstract_t\">Lautenschlager S, Schwarzkopf S, Keller B. Exophytic ulcerated tumors in HIV patients: diagnostic and therapeutic problems. Dermatology 2008; 216:60.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/44\" class=\"nounderline abstract_t\">Samaratunga H, Weedon D, Musgrave N, McCallum N. Atypical presentation of herpes simplex (chronic hypertrophic herpes) in a patient with HIV infection. Pathology 2001; 33:532.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/45\" class=\"nounderline abstract_t\">Ranu H, Lee J, Chio M, Sen P. Tumour-like presentations of anogenital herpes simplex in HIV-positive patients. Int J STD AIDS 2011; 22:181.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/46\" class=\"nounderline abstract_t\">Husak R, Tebbe B, Goerdt S, et al. Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient. Br J Dermatol 1998; 139:118.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/47\" class=\"nounderline abstract_t\">Plowman GM, Watson MW, D'Souza H, Thomas MG. Obstructive endo-bronchial pseudotumour due to herpes simplex type 2 infection in an HIV-infected man. Int J STD AIDS 2009; 20:737.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/48\" class=\"nounderline abstract_t\">Tong P, Mutasim DF. Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease. Br J Dermatol 1996; 134:797.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/49\" class=\"nounderline abstract_t\">Baras L, Farber CM, Van Vooren JP, Parent D. Herpes simplex virus tracheitis in a patient with the acquired immunodeficiency syndrome. Eur Respir J 1994; 7:2091.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/50\" class=\"nounderline abstract_t\">Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. Drugs 2007; 67:155.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/51\" class=\"nounderline abstract_t\">Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis 2003; 30:310.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/52\" class=\"nounderline abstract_t\">Safrin S, Arvin A, Mills J, Ashley R. Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 in patients with AIDS. J Clin Microbiol 1992; 30:1312.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/53\" class=\"nounderline abstract_t\">Ahmed HJ, Mbwana J, Gunnarsson E, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. Sex Transm Dis 2003; 30:114.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/54\" class=\"nounderline abstract_t\">Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect 2007; 83:16.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/55\" class=\"nounderline abstract_t\">Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011; 117:1089.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/56\" class=\"nounderline abstract_t\">Green T, Rogstad KE, Paterson ME. Genital herpes may mask underlying neoplasia. Sex Transm Infect 2001; 77:148.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/57\" class=\"nounderline abstract_t\">Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguideline s/adult_oi.pdf (Accessed on November 04, 2015).</li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on July 10, 2017).</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/60\" class=\"nounderline abstract_t\">Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143:707.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-in-hiv-infected-patients/abstract/61\" class=\"nounderline abstract_t\">Magaret AS, Mujugira A, Hughes JP, et al. Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clin Infect Dis 2016; 62:456.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 16254 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H6231095\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H6231103\" id=\"outline-link-H6231103\">INTRODUCTION</a></li><li><a href=\"#H970262\" id=\"outline-link-H970262\">DEFINITIONS</a><ul><li><a href=\"#H970224\" id=\"outline-link-H970224\">Primary</a></li><li><a href=\"#H970231\" id=\"outline-link-H970231\">Nonprimary</a></li><li><a href=\"#H970361\" id=\"outline-link-H970361\">Reactivation disease</a></li></ul></li><li><a href=\"#H2392163\" id=\"outline-link-H2392163\">EPIDEMIOLOGY</a></li><li><a href=\"#H2392466\" id=\"outline-link-H2392466\">NATURAL HISTORY</a><ul><li><a href=\"#H744885\" id=\"outline-link-H744885\">Clinical disease</a></li><li><a href=\"#H744892\" id=\"outline-link-H744892\">Viral shedding</a></li><li><a href=\"#H13152652\" id=\"outline-link-H13152652\">Effect of antiretroviral therapy on HSV-2-related disease</a></li></ul></li><li><a href=\"#H11525287\" id=\"outline-link-H11525287\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H6231117\" id=\"outline-link-H6231117\">Ulcerative disease</a></li><li><a href=\"#H6231124\" id=\"outline-link-H6231124\">Hypertrophic masses and pseudotumors</a></li><li><a href=\"#H6231138\" id=\"outline-link-H6231138\">Other unusual manifestations of HSV disease</a></li></ul></li><li><a href=\"#H6231152\" id=\"outline-link-H6231152\">DIAGNOSIS</a><ul><li><a href=\"#H11525273\" id=\"outline-link-H11525273\">Ulcerative disease</a></li><li><a href=\"#H11525280\" id=\"outline-link-H11525280\">Hypertrophic lesions</a></li><li><a href=\"#H12678014\" id=\"outline-link-H12678014\">Patients with a recent history of genital disease</a></li></ul></li><li><a href=\"#H11524576\" id=\"outline-link-H11524576\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H11524735\" id=\"outline-link-H11524735\">SCREENING FOR HSV-2 INFECTION</a></li><li><a href=\"#H2974930377\" id=\"outline-link-H2974930377\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H6231095\" id=\"outline-link-H6231095\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/16254|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/81569\" class=\"graphic graphic_picture\">- Severe mucosal HSV-2 ulceration in an HIV woman</a></li><li><a href=\"image.htm?imageKey=ID/63362\" class=\"graphic graphic_picture\">- Hypertrophic lesion due to HSV-2 in an HIV-infected woman</a></li><li><a href=\"image.htm?imageKey=ID/75196\" class=\"graphic graphic_picture\">- HSV-2 lesion mimicking condyloma accuminata in HIV patient</a></li></ul></li><li><div id=\"ID/16254|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/80693\" class=\"graphic graphic_table\">- Clinical designation of genital herpes simplex virus infection</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-genital-ulcers\" class=\"medical medical_review\">Approach to the patient with genital ulcers</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=condylomata-acuminata-anogenital-warts-in-adults-epidemiology-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=effect-of-herpes-simplex-virus-on-hiv-infection-implications-for-hiv-prevention\" class=\"medical medical_review\">Effect of herpes simplex virus on HIV infection: Implications for HIV prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hiv-infection-and-malignancy-epidemiology-and-pathogenesis\" class=\"medical medical_review\">HIV infection and malignancy: Epidemiology and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-genital-herpes-virus-infections\" class=\"medical medical_review\">Prevention of genital herpes virus infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: Opportunistic infections in HIV-infected adults and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-sexually-transmitted-infections\" class=\"medical medical_society_guidelines\">Society guideline links: Sexually transmitted infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-resistant-genital-herpes-simplex-virus-infection-in-hiv-infected-patients\" class=\"medical medical_review\">Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-type-2-in-hiv-infected-patients\" class=\"medical medical_review\">Treatment of genital herpes simplex virus type 2 in HIV-infected patients</a></li></ul></div></div>","javascript":null}